Lancet子刊:华中科大:与专家水平相当——深度学习盆腔超声对“女性杀手”卵巢癌的诊断准确性

2022-03-18 MedSci原创 MedSci原创

启用DCNN的超声性能超过了放射科医生的平均诊断水平,与专家级超声图像阅读器的水平相匹配,并增强了放射科医生的准确性。

超声是卵巢癌术前诊断的重要非侵入性检查。深度学习在图像识别任务方面正在取得进展;为此,来自我国华中科技大学附属同济医院的妇产科专家领衔全国多中心旨在开发一个深度卷积神经网络(DCNN)模型,使超声图像的评估自动化,并促进比现有方法更准确的卵巢癌诊断。

在这项回顾性、多中心的诊断研究中,研究人员收集了2003年9月至2019年5月期间全国十家医院的盆腔超声图像。纳入了超声检查中附件病变的连续成年患者(年龄≥18岁)和健康对照组,排除了重复病例和没有附件或病理诊断的患者。

对于DCNN模型的开发,患者被分配到训练数据集(3755名卵巢癌患者的34 488张图像,101777名对照的541442张图像)。对于模型验证,患者被分配到内部验证数据集,外部验证数据集。利用这些数据集评估了DCNN的诊断价值,将DCNN与35名放射科医生进行了比较,并探讨了DCNN是否能提高6名放射科医生的诊断准确性。

对于DCNN检测卵巢癌,内部数据集的AUC为0.911(95% CI 0.886-0.936),外部验证数据集1为0.870(95% CI 0.822-0.918),而外部验证数据集2为0.831(95% CI 0.793-0.869)。在内部数据集(88.8% vs 85.7%)和外部验证数据集1(86.9% vs 81.1%)中,DCNN模型在检测卵巢癌方面比放射科医生更准确。

在DCNN辅助诊断后,诊断的准确性和敏感性比单独由放射科医生评估增加得更多(87.6% [85.0-90.2] vs 78.3% [72.1-84.5];82.7% [78.5-86.9] vs 70.4% [59.1-81.7])。六位放射科医生的DCNN辅助评估的平均准确率达到0.876,并且在DCNN辅助评估时,其准确率明显增强。

综上,启用DCNN的超声性能超过了放射科医生的平均诊断水平,与专家级超声图像阅读器的水平相匹配,并增强了放射科医生的准确性。

 

参考文献:

Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study. https://doi.org/10.1016/S2589-7500(21)00278-8

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1831501, encodeId=b47f183150153, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 07:33:44 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906012, encodeId=c04519060128d, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 28 07:33:44 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664804, encodeId=7dd6166480442, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Sep 13 04:33:44 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992916, encodeId=1bff1992916af, content=<a href='/topic/show?id=f68e9158034' target=_blank style='color:#2F92EE;'>#诊断准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91580, encryptionId=f68e9158034, topicName=诊断准确性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue Nov 08 02:33:44 CST 2022, time=2022-11-08, status=1, ipAttribution=)]
    2022-12-12 howi

    #Lancet#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1831501, encodeId=b47f183150153, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 07:33:44 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906012, encodeId=c04519060128d, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 28 07:33:44 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664804, encodeId=7dd6166480442, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Sep 13 04:33:44 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992916, encodeId=1bff1992916af, content=<a href='/topic/show?id=f68e9158034' target=_blank style='color:#2F92EE;'>#诊断准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91580, encryptionId=f68e9158034, topicName=诊断准确性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue Nov 08 02:33:44 CST 2022, time=2022-11-08, status=1, ipAttribution=)]
    2022-12-28 lilianxiang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1831501, encodeId=b47f183150153, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 07:33:44 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906012, encodeId=c04519060128d, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 28 07:33:44 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664804, encodeId=7dd6166480442, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Sep 13 04:33:44 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992916, encodeId=1bff1992916af, content=<a href='/topic/show?id=f68e9158034' target=_blank style='color:#2F92EE;'>#诊断准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91580, encryptionId=f68e9158034, topicName=诊断准确性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue Nov 08 02:33:44 CST 2022, time=2022-11-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1831501, encodeId=b47f183150153, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 07:33:44 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906012, encodeId=c04519060128d, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 28 07:33:44 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664804, encodeId=7dd6166480442, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Sep 13 04:33:44 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992916, encodeId=1bff1992916af, content=<a href='/topic/show?id=f68e9158034' target=_blank style='color:#2F92EE;'>#诊断准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91580, encryptionId=f68e9158034, topicName=诊断准确性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue Nov 08 02:33:44 CST 2022, time=2022-11-08, status=1, ipAttribution=)]

相关资讯

J Clin Oncol:派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效

派姆单抗在既往接受过治疗的晚期 MSI-H/dMMR 子宫内膜癌患者中显示出了强大而持久的抗肿瘤活性,并显示出令人鼓舞的生存预后,而且毒性可控。

Front Oncol:新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效

研究表明,对于FIGO IIIB、IIIC和IV型卵巢癌患者伴有不同BRCA1/2生殖系突变状态,NAC-IDS并未对生存结果产生不利影响。

梅斯盘点:2021年度妇瘤领域十大进展

1、卵巢癌精准诊断和治疗取得进展

Clin Cancer Res:Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌

Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌具有初始的治疗活性

Clin Cancer Res:奥拉帕尼单药维持治疗亚洲铂敏感的复发性卵巢癌患者的疗效

在亚洲铂敏感的复发性卵巢癌患者中,奥拉帕尼维持治疗具有较高的治疗活性和良好的耐受性

Clin Cancer Res:PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效

Pamiparib在携带gBRCAmut的铂敏感性卵巢癌或铂耐药性卵巢癌患者中都展现出了较持久的抗肿瘤活性

拓展阅读

论文解读| 破解卡铂耐药性:正向遗传学揭示HN1L/JPT2是卵巢癌逃避铂类治疗的新参与者

该研究采用基于验证的插入突变(VBIM)技术,识别出HN1L/JPT2是卵巢癌细胞对卡铂耐药的新基因。

【论著】|外泌体中ISG15在卵巢癌铂类药物耐药中的作用及初步机制探讨

本文基于蛋白质组学等技术,鉴定出卵巢癌外泌体中的关键蛋白分子,明确其在卵巢癌细胞耐药性中的作用,为预测卵巢癌耐药提供新的思路。

生存结局双重获益,总生存期近16个月!这类卵巢癌或有新标准治疗方案 | 2025 ASCO速递

2025 年 ASCO 发布的 ROSELLA 研究显示,relacorilant 联合白蛋白紫杉醇治疗铂耐药复发性卵巢癌,较单药显著延长 PFS和 OS,安全性可控,有望成新标准。

Mol Cell:重庆医科大学易萍等证明抑制YTHDF2会阻碍卵巢癌的进展,并增强卵巢癌细胞对紫杉醇的敏感性!

该研究证明YTHDF2与真核翻译起始因子eIF3F和RNA解旋酶DDX1形成明显的相互作用,从而增强肿瘤细胞中的蛋白质合成。

HRD阳性为啥疗效不佳,阴性为啥有效?晚期卵巢癌应用PARP抑制剂还应关注这些基因变异

本研究结果突显了晚期卵巢癌中对PARPi反应的复杂性,并强调了探索HRD状态之外的体细胞变异的重要性。有必要进一步研究BRCA1外显子11变异以及联合治疗的潜力。

卵巢癌中HRR相关基因胚系变异的发生率为12.8%,浆液性癌和III/IV期患者中更为常见

本研究旨在确定EOC患者中与癌症易感性相关基因的变异频率,确定与这些基因PVs相关的临床特征,并根据HRR状态评估它们对预后的影响。